Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

78.73EUR
3:57pm GMT
Change (% chg)

€-0.50 (-0.63%)
Prev Close
€79.23
Open
€79.11
Day's High
€79.86
Day's Low
€78.41
Volume
917,522
Avg. Vol
2,464,309
52-wk High
€80.44
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.32 31.23 33.59
EPS (TTM): 3.70 -- --
ROI: 5.69 15.57 15.05
ROE: 8.50 16.94 16.62

Berkshire invests in JPMorgan, Oracle as Buffett puts cash to work

Warren Buffett's Berkshire Hathaway Inc deepened its commitment to the U.S. financial industry, announcing a $4.02 billion stake in JPMorgan Chase & Co and new investments in PNC Financial Services Group Inc and Travelers Companies Inc, plus a stake in Oracle Corp.

14 Nov 2018

UPDATE 3-Berkshire invests in JPMorgan, Oracle as Buffett puts cash to work

Nov 14 Warren Buffett's Berkshire Hathaway Inc deepened its commitment to the U.S. financial industry, announcing a $4.02 billion stake in JPMorgan Chase & Co and new investments in PNC Financial Services Group Inc and Travelers Companies Inc, plus a stake in Oracle Corp .

14 Nov 2018

BRIEF-Sanofi: Analyses On Mortality From ODYSSEY OUTCOMES Trial Of Praluent

* ANNOUNCED ON SUNDAY ANALYSES ON MORTALITY FROM THE 18,924-PATIENT ODYSSEY OUTCOMES TRIAL

12 Nov 2018

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

06 Nov 2018

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron , the companies said on Tuesday.

06 Nov 2018

UPDATE 1-Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS, Nov 6 The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

06 Nov 2018

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA - companies

PARIS, Nov 6 The U.S. Food & Drug Administration (FDA) regulator gave more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

06 Nov 2018

Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations.

31 Oct 2018

Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations.

31 Oct 2018

UPDATE 2-Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS, Oct 31 Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations.

31 Oct 2018

Earnings vs. Estimates